We love to hear from our listeners. Send us a message.

Allan Shaw isn't the only insider who's preemptively critical of the impact the IRA (Inflation Reduction Act) will have on the biopharma industry.  Allan's back this week with analysis of what he and others are tongue-in-cheek calling the "innovation reduction act." He posits that the act's removal of certain protections  will stifle momentum by disincentivizing the pursuit of novel discoveries in molecules small and large. He also suggests that the impact of the IRA will ultimately cost patients and payers more. Tune in to learn why.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: [email protected]

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/